# Rituximab (RTX) Therapy in Patients With Active TAO

> **NCT02378298** · PHASE4 · COMPLETED · sponsor: **Göteborg University** · enrollment: 38 (actual)

## Conditions studied

- Ophthalmopathy, Thyroid-Associated

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Iv Methylprednisolone
- **DRUG:** peroral methylprednisolone and Methotrexate

## Key facts

- **NCT ID:** NCT02378298
- **Lead sponsor:** Göteborg University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2019-09-03
- **Final completion:** 2020-02-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378298, "Rituximab (RTX) Therapy in Patients With Active TAO". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02378298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*